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ing author. Tel.: +1 516
ess: nsuhdo@yahoo.comSummary Gemcitabine is a newer pyrimidine analog used for the treatment of
solid tumors. Though generally considered safe, it can cause pulmonary toxicity,
which is generally mild and reversible. The purpose of this publication is to
document a case of adult respiratory distress syndrome (ARDS) caused by
Gemcitabine administration. The patient was noticed to have the extreme elevation
of erythrocyte sedimentation rate (ESR) (4100mm/h) at the time of diagnosis. We
observed excellent response to the corticosteroids. The ESR trended back to normal
after the resolution of her symptoms thereby suggesting the utility of monitoring ESR
in the diagnosis and management of Gemcitabine-induced pulmonary toxicity.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Respiratory symptoms as adverse reaction to
medication intake are a common phenomenon.
Many types of pulmonary problems such as shortness
of breath, cough, fibrosis, and pleural effusions are
very well documented. However, drug-induced pul-
monary edema is relatively rare. Recognition of this is
especially problematic in a patient with multiple
comorbidities.Elsevier Ltd. All rights reserve
708 1263.
(S. Davidoff).We present a case of Gemcitabine-induced
pulmonary edema. Throughout the course, the
patient was noticed to have an extreme elevation
of erythrocyte sedimentation rate (ESR). To our
knowledge, this is the first attempt to utilize ESR in
the face of Gemcitabine-induced pulmonary ede-
ma. The level was monitored. Our implication is
that a patient presenting with shortness of breath,
bilateral infiltrations on the chest X-ray, leukocy-
tosis, and extreme ESR elevation can at times be
exhibiting signs of drug-induced pulmonary toxicity.
Along with the overall symptomatology, monitoring
the ESR levels can be attempted to observe the
response to the ongoing therapy.d.
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A 60-year-old female was diagnosed with Carcino-
ma of the right breast in 1998, for which she
underwent lumpectomy with subsequent radiation
therapy. She was treated with Tamoxifen and
remained asymptomatic until July 2003, when she
was diagnosed with metastatic disease in the spinal
column, liver and contralateral breast. She re-
ceived five cycles of Vinorelbine from July 2003 to
April 2004.
In April 2004, the patient was started on
Gemcitabine (1424mg weekly for 3 weeks of the
month). The total of five cycles of Gemcitabine was
tolerated well. Her last dose was given 7 days prior
to the admission.
The patient was admitted through the emer-
gency room with progressive shortness of breath
and non-productive cough for few days. Three days
prior to the admission, she was started on Levaquin
for presumptive diagnosis of acute bronchitis.
Despite that, shortness of breath continued to
worsen.
Her physical examination revealed a blood pres-
sure of 170/87mmHg, and pulse rate of 122 beats
per minute, respiratory rate of 32 breaths per
minute. The patient’s oxygen saturation was 72%
on room air. She was placed on 100% oxygen via
facial mask, and the oxygen saturation improved to
91%. Mild jugular vein distention was noticed. Chest
examination revealed use of accessory musculature,
and bibasilar rhonchi were appreciated on ausculta-
tion. There were no audible heart murmurs.
Abdominal and neurological exams were unremark-
able. Examination of the extremities did not show
any edema. Distal pulses were palpable.
The chest radiograph (Fig. 1) at the time of
admission revealed diffuse, bilateral, multifocal
opacities indicative of air space disease without signi-
ficant pleural effusion. There was no cardiomegaly.
Laboratory examination demonstrated leukocy-
tosis of 17,300 cells/mm3 (neutrophills 80%, lym-
phocytes 16%, eosinophills 1% and monocytes 3%),
mild anemia (hemoglobin of 10.1 g/dL and hema-
tocrit of 29.5%) and platelets of 167,000/mL.
Arterial blood gas analysis while the patient was
on FiO2 of 100% demonstrated pH 7.44; pCO2
42mmHg; pO2 64mmHg. Patient’s blood, sputum
and urine samples were sent for cultures. A CT scan
of the chest (Fig. 2) showed extensive ground-glass
opacities throughout both lungs, more so in both
upper lobes. Interlobular septal thickening and
small bilateral pleural effusions were also seen.
The patient was initially treated with Albuterol
and Ipratropium given via hand-held nebulizer and
intravenous Lasix 40mg. Levaquin 500mg orally perday was continued for possible Community acquired
pneumonia. Because of the lack of improvement,
Levaquin was discontinued on the 2nd day of
hospitalization and the patient was started on
Vancomycin 1 g/day intravenously and Ceftazidime
2 g every 12 h intravenously. The patient underwent
bronchoscopy but broncho-alveolar lavage did not
reveal an infectious cause of the pulmonary
process. Repeated microbiological evaluation of
the blood was also negative. She continued to
remain hypoxemic and her ESR was found to be
128mm/h. As the diagnosis of Gemcitabine related
pulmonary toxicity was entertained, the patient
was started on Solu-Medrol 40mg intravenously
every 12 h.
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Figure 3
S. Davidoff et al.762There was a significant clinical response to the
steroids. The patient’s dyspnea improved. She was
able to maintain adequate oxygenation (oxygen
saturation of 94% while being supplemented with
oxygen via nasal canula at the rate of 4 L/min). On
the 5th day of the steroid therapy, the patient’s
oxygen saturation was stable at 96% on 2 L/min of
oxygen via nasal canula. On the 8th day of the
steroid treatment, the oxygen saturation was
94–96% without any supplementation. The repeat
CT scan of the chest also showed almost complete
resolution of the infiltrates seen on the first CT scan
of the chest (Fig. 3). As the clinical symptomatol-
ogy improved, the ESR showed a downward trend.
Four day after starting the steroids, the ESR was
89mm/h; and on the 10th day of the treatment, it
went down to 59mm/h. A total 14-day course of
steroids was given. Ten days after the discontinua-
tion, the ESR was found to be 41mm/h and
pulmonary function test did not reveal significant
abnormalities.Discussion
Gemcitabine-induced pulmonary toxicity can cause
respiratory dysfunction. Only a few cases of adult
respiratory distress syndrome (ARDS) due to Gem-
citabine have been reported.1,2 The onset of the
pulmonary toxicity cannot be predicted and the
time course of this complication is variable.3–5
There seems to be no relationship between the
dose and the severity of the pulmonary insult.6 Pasthistory of radiation therapy to the chest and older
age seem to be the predisposing factors.7 Most
commonly reported symptom is dyspnea, occurring
in about 8% cases.5,8 ARDS associated with Gemci-
tabine is rare with the incidence of 0.002%.9 The
exact mechanism of the severe lung damage is not
clear5 but autopsy reports describe diffuse alveolar
damage as the pathological manifestation of the
acute respiratory failure.10
The underlying pathological mechanism of pul-
monary insult can be to be two-fold. Commonly,
Gemcitabine simply causes hypersensitivity reac-
tion, which is self-limited and improves with the
discontinuation of the drug. However, it seems that
Gemcitabine is capable of inducing direct endothe-
lial damage to the pulmonary vasculature that can
be severe enough to result life-threatening non-
cardiogenic pulmonary edema.11 Therefore, early
initiation of the corticosteroids and a diuretic agent
can be life saving12,13 after the infectious etiology
of the process is excluded.
Etiology of progressive hypoxemia and bilateral
infiltrates on chest X-ray in a patient receiving
Gemcitabine is complex and timely recognition of
the problem quite often presents a challenge and
remains a diagnosis of exclusion.4 Even though
some patients respond well to withholding of the
drug and watchful waiting, the rapidity of the
development of respiratory failure underscores the
need for highly efficient work-up.
Elevation of ESR is known to be associated with
drug toxicity syndromes.14 To our knowledge, this is
the first report that describes ESR elevation in
association with Gemcitabine-induced pulmonary
edema. In addition, we were able to observe that
improvement in the clinical picture correlates with
changes in ESR. Therefore, we suggest that in the
appropriate clinical setting, elevated ESR, and
worsening hypoxemia with bilateral infiltrates
on chest X-ray, Gemcitabine-induced pulmonary
toxicity should be considered in the differential
diagnosis. Serial measurement of the ESR may
be attempted to monitor clinical response to
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